Literature DB >> 16336491

Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers.

Mark J Atkinson1, Ritesh Kumar, Joseph C Cappelleri, Steven L Hass.   

Abstract

OBJECTIVES: The objectives of this study were twofold: 1) to evaluate the construct validity of the Treatment Satisfaction Questionnaire for Medication (TSQM v. II) using structural equation modeling (SEM); and 2) to assess its concurrent validity using medication adherence criteria.
METHODS: Pharmacy patients filling a new medication prescription (n = 342) were recruited from 14 Michigan pharmacies to participate in a 4-week treatment satisfaction study. The TSQM v. II was tested for model fit against an established theoretical model (the Decisional Balance Model of Treatment Satisfaction) using hierarchical confirmatory factor analysis (HCFA). Regression and discriminant analytic models were used to examine the criterion-related validity of the measure.
RESULTS: An exploratory factor analysis, used for TSQM v. II item reduction, revealed a strongly dimensional instrument (Effectiveness, Side Effects, and Convenience) and explained 88% of total pooled variance. Results of an HCFA using the final TSQM v. II items suggested a good model fit with the data (P > 0.54). In support of concurrent validity, the TSQM scales explained between 9% and 20% of the variance in dosing adherence and 60% of the variance in the likelihood of future use. Discriminant analysis demonstrated the superior classification power of the hierarchical model of treatment satisfaction over the discrete attribute model when predicting medication discontinuation.
CONCLUSIONS: The TSQM v. II has equivalent measurement characteristics as the TSQM v. I, yet uses four fewer items and more consistent wording. The value of the Decisional Balance Model for estimation of dosing adherence and medication persistence over time is discussed.

Entities:  

Mesh:

Year:  2005        PMID: 16336491     DOI: 10.1111/j.1524-4733.2005.00066.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  105 in total

1.  Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela Paraiso; Shawn A Menefee; Joseph Schaffer; John Wei; Toby Chai; Nancy Janz; Cathie Spino; Susan Meikle
Journal:  Contemp Clin Trials       Date:  2011-10-08       Impact factor: 2.226

2.  Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation.

Authors:  Luca Neri; Guido Basilisco; Enrico Corazziari; Vincenzo Stanghellini; Gabrio Bassotti; Massimo Bellini; Ilaria Perelli; Rosario Cuomo
Journal:  United European Gastroenterol J       Date:  2014-04       Impact factor: 4.623

3.  Assessing the impact of non-severe hypoglycemic events and treatment in adults: development of the Treatment-Related Impact Measure-Non-severe Hypoglycemic Events (TRIM-HYPO).

Authors:  Meryl Brod; Lise Højbjerre; Donald M Bushnell; Charlotte Thim Hansen
Journal:  Qual Life Res       Date:  2015-06-21       Impact factor: 4.147

4.  Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

Authors:  H B Niebur; C M Duff; G F Shear; D Nguyen; T K Alberdi; M J Dorsey; J W Sleasman
Journal:  Clin Exp Immunol       Date:  2015-07-07       Impact factor: 4.330

5.  Treatment Satisfaction, Product Perception, and Quality of Life in Plaque Psoriasis Patients Using Betamethasone Dipropionate Spray 0.05.

Authors:  Joseph F Fowler; James Q Del Rosso; Refika I Pakunlu; Srinivas Sidgiddi
Journal:  J Clin Aesthet Dermatol       Date:  2017-11-01

6.  Relationship of treatment satisfaction to health-related quality of life: findings from a cross-sectional survey among hypertensive patients in Palestine.

Authors:  Samah W Al-Jabi; Sa'ed H Zyoud; Waleed M Sweileh; Aysha H Wildali; Hanan M Saleem; Hayat A Aysa; Mohammad A Badwan; Rahmat Awang
Journal:  Health Expect       Date:  2014-12-07       Impact factor: 3.377

7.  Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.

Authors:  Meryl Brod; Paul Valensi; Joseph A Shaban; Don M Bushnell; Torsten L Christensen
Journal:  Qual Life Res       Date:  2010-07-04       Impact factor: 4.147

8.  Development and validation of a questionnaire on 'Satisfaction with dermatological treatment of hand eczema' (DermaSat).

Authors:  Miguel A Ruiz; Felipe Heras; Agusti Alomar; Luis Conde-Salazar; Jesús de la Cuadra; Esther Serra; Francisco Regalado; Ralf Halbach
Journal:  Health Qual Life Outcomes       Date:  2010-11-05       Impact factor: 3.186

9.  Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options.

Authors:  Gosia Sylwestrzak; Jinan Liu; Judith J Stephenson; Alexander P Ruggieri; Andrea DeVries
Journal:  Am Health Drug Benefits       Date:  2014-04

10.  Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications.

Authors:  Murtuza Bharmal; Krista Payne; Mark J Atkinson; Marie-Pierre Desrosiers; Donald E Morisky; Eric Gemmen
Journal:  Health Qual Life Outcomes       Date:  2009-04-27       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.